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In this issue, Ishizuka et al. (2008) define human T cell-receptor recognition of an immunodominant influenza
A matrix peptide bound to human leukocyte antigen HLA-A*0201 in atomic detail, raising provocative
questions about b chain function.A key feature of ab T cell receptor (TCR)
recognition that emerged from the initial
wave of structures of TCRs in complex
with peptide-bound major histocompati-
bility complex (pMHC) is that each TCR
assumes a common diagonal docking
mode on the pMHC with its Va domain
docking over the N-terminal portion of
the antigenic peptide and the Vb domain
docking over the C-terminal part (Rudolph
et al., 2006; Teng et al., 1998). The inher-
ent twist of the b sheet platform that forms
the floor ofMHCmolecule’s antigen-bind-
ing groove forces the two long a helices
on the wall of the groove to each break
into two segments, creating two peaks
on the pMHC molecular surface. In order
for the TCR to probe sufficiently deep
into the MHC groove to make requisite
contact with an antigenic peptide, a diag-
onal binding geometry is required to slot
between the two peaks.Within this frame-
work, binding variations in twist, tilt, and
shift are observed. However, the general
principles governing TCR-pMHC recogni-
tion and subsequent signal transduction
remain essentially uncharted.
Ishizuka et al. (2008), in this issue of
Immunity, now provides a close-up view
of one important issue in the TCR field:
the basis for immunodominance. Immu-
nodominance refers to the phenomenon
whereby after infection (or upon vaccina-
tion) the T cell immune response rapidly
focuses on a very small number of epi-
topes out of an immensely large pool of
potential epitopes. The mechanisms un-
derlying T cell immunodominance are
complex and poorly understood. Effective
antigen processing, presentation copynumber, and peptide-MHC binding kinet-
ics, as well as T cell recognition, all affect
the dominance of a very few peptides.
Unique structural features of peptides
presented on MHC surfaces can be im-
portant in selection of the corresponding
immunodominant cytotoxic T lymphocyte
(CTL) repertoire (Doherty et al., 2006;
Meijers et al., 2005).
Ishizuka et al. (2008) investigate the hu-
man TCR-JM22 interaction with an im-
munodominant influenza matrix peptide
(amino acids 58–66 with sequence
GILGFVFTL) presented by the class I
MHC molecule HLA-A*0201. This TCR in-
corporates the Vb17 gene segment com-
mon to virtually all matrix-HLA-A*0201-
specific T cells in humans (Ishizuka
et al., 2008). The intriguing question asked
is what makes a flat and featureless
‘‘vanilla’’ flu peptide immunodominant. In
2003, the same group determined the
high-resolution crystal structure of Vb17
TCR-HLA-A2-flu, revealing clues to the
structural basis for predominant usage
of the Vb17 domain in HLA-A2-flu recog-
nition. The highly selected amino acid se-
quence motif RSSY was identified in the
CDR3b loop of the JM22 TCR as playing
an essential role in peptide recognition.
Particularly, the conserved Arg98b side
chain on the loop docks into a notch
formed between the peptide and HLA-
A2. Moreover, side chains from CDR1b
and CDR2b loops also hydrogen bond to
the peptide, providing recognition speci-
ficity. The high-resolution JM22 TCR-
pMHC-complex structure allowed them
to scrutinize the interaction interface with
12 key contacting residues on JM22. InImmunitytheir new study, extensive kinetic and
thermodynamic measurements were
made with the employment of a series of
rationally designed mutant JM22 TCRs.
They systematically examine which resi-
dues are affinity determinants. At the
same time, they determined more crystal
structures of the JM22 TCR, wild-type or
mutant, liganded and unliganded.
These biochemical, structural, and mu-
tational analyses on the interaction inter-
face identified a binding ‘‘hot spot’’ within
the Vb domain. Strikingly the majority of
hot-spot residues are the germline-en-
coded Gln52b and Ile53b of CDR2b and
Asp32b of CDR1b. Arg98b of CDR3b is
the only crucial contributor from the
nongermline-encoded hypervariable re-
gion. It is particularly interesting to note
that the germline-encoded Gln52b and
Asp32b residues are unique to the Vb17
segment and that the Gln52Ala mutation
completely abrogates any detectable
binding. In the structure, the amido group
of this Gln52b residue makes two hydro-
gen bonds to the peptide backbone, one
to the carbonyl oxygen of Gly4 and the
other to the amide group of Val6 of the
peptide (Figure 1). The peptide actually
arches out of the pMHC surface at the
Gly4. The dihedral angles at the sharply
bent position 4 are 92 and 5, a confor-
mation most favored for glycine to as-
sume. It is conceivable that Gln52b has
been preselected to recognize the back-
bone conformation of this particular anti-
genic peptide. In terms of sidechain
recognition, the peptide is indeed feature-
less. N-terminal to Gly4, the peptide is
entirely buried within the MHC molecule.28, February 2008 ª2008 Elsevier Inc. 139
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PreviewsFigure 1. Immunodominance and b Chain Recognition of pMHC
Details of the JM22-HLA-A*0201-bound matrix-peptide interaction. The TCR Vb CDR loops appear at the
top in green and blue, whereas the influenza A peptide is shown at the bottom in red. Residues discussed
in the text are labeled, and hydrogen bonds are shown as dotted lines.The only prominent sidechain exposed
from the pMHC surface to be seen by
the TCR is that of Thr8. Its hydroxyl oxy-
gen hydrogen bonds to Asp32b, whereas
its methyl group makes a van der Waals
contact to Ile53b. The peptide has two
barely exposed phenol rings from Phe5
and Phe7. They contribute to notch-like
binding by Arg98b as mentioned above.
Furthermore, Arg98b forms three hydro-
gen bonds to the a2 helix of HLA and
one to the peptide via a water molecule.
Therefore, the biochemical data agree
extremely well with the high-resolution
structure, explaining the critical role
played by the four residues in the hotspot
of the conserved Vb17 in recognition of
the featureless immunodominant peptide.
Conservation among TCRs from T cells
responding toan immunodominant pMHC
ligand has been observed previously.
Most extreme is the example of the hu-
man immune response in HLA-B8 individ-
uals to Epstein-Barr virus latent antigen
EBNA3A. CTLs with this specificity from
unrelated individuals utilize the same
TCR a and b pair. The structural basis
for this selective dominance of a single
ab public clonotype has been elegantly
described (Kjer-Nielsen et al., 2003). A
third example, with conservation of the
Vb domain and a highly variable Va usage,140 Immunity 28, February 2008 ª2008 Elseis found in B6 mice to the immunodomi-
nant Db-restricted NP366-374 influenza
A peptide from the nucleoprotein after
PR8 viral infection. The repertoire is highly
biased, with prominent TRBV13-1:
TRBD1:TRBJ2-2 gene segment combina-
tion usage and selection of nine amino
acid long CDR3b segments with a GxN
sequence motif (Zhong et al., 2007, and
references therein). It was suggested
that conserved amino acid residues in
the germline-encoded regions of a TCR
Vb subfamily member might favor key
contacts with residues of a given pMHC
complex, resulting in biased Vb segment
usage. Incorporation of such immunopro-
tective features of immune recognition
into the germline then allows for ready
selection of useful TCRs that are further
improved upon by structurally relevant
CDR3 segments. Certainly the example
described by Ishizuka et al. (2008) is con-
sistent with this notion. Of note, however,
is that unlike with the highly biased TCR
Vb repertoire, the associated Va reper-
toire specific for the NP366–374/Db ligand
remains extremely diverse, even after
secondary viral infection.
In each of the examples above, the Vb
domain plays a key role in TCR-based
recognition. The recent suggestion of
potential germline-derived TCR-MHCvier Inc.pairwise interaction motifs, or ‘‘codons,’’
linked to MHC restriction also pointed to
highly biased Vb domain selection (Feng
et al., 2007). The observations raise the in-
teresting possibility as to whether Vb rec-
ognition itself can mediate a physiologic
binding event within the immune system.
If this were the case, then one could imag-
ine how pairing of different Va domains to
the single Vb domain could result in a
broader range of T cell repertoire recog-
nition against variant epitopes, thereby
curtailing or at least minimizing escape
from CTL control. This variable a pairing
with a conserved b chain would not just
broaden protection against the N-terminal
portion of the MHC-bound peptide where
the Va domain largely interacts but would
also impact theC-terminal end of the pep-
tide, because the VaVb pairing influences
the configuration of Vb CDR loops (Zhong
et al., 2007). The concept that a single
chain of an immune receptor exerts dom-
inance has precedence in antibodies
where the heavy chain is the major deter-
minant of antigen affinity and specificity.
Camelids, in fact, possess a functional
class of antibodies devoid of light chain
(Desmyter et al., 1996). Important ques-
tions are the following: Could the pre-
TCR, consisting of a pTa-b heterodimer
with an unpaired Vb domain, functionally
interact with MHC molecules in the thy-
mus during b selection (von Boehmer,
2005) to begin the process of repertoire
formation? Might b dominance in certain
viral responses as shown here or in the al-
loreactive T cell response result from such
a ligand-binding function? And, last but
not least, are the subtle TCR conforma-
tional changes noted by Ishizuka et al.
(2008) upon pMHC ligand binding a basis
for selection or signaling? Time will tell. As
always, quality studies raise more ques-
tions than they answer.
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New findings by Hughes et al. (2008
apoptosis regulators Bim and Fas
of failure of this process.
If the immune system were a television
game show, the announcer might sum-
marize the rules at the outset in this ab-
breviated way: ‘‘You know how we play:
Each lymphocyte contestant recognizes
a different antigenic determinant, and if
they find it, they proliferate to make the
most effective immune response to win
the game. And that’s all there is to it!’’
But real life is not reality TV, and a funda-
mental, if simple, problem with this ‘‘con-
test’’ quickly reveals itself—the expansion
of lymphocytes in a few immune re-
sponses will overrun the system, preclud-
ing subsequent responses to new anti-
gens, unless they can die rapidly enough
to clear the way. And to make matters
worse, any elicited responses that have
an autoimmune component will wreak
havoc. Now, three papers in this issue of
Immunity (Hughes et al., 2008; Hutcheson
et al., 2008; Weant et al., 2008) give us
some idea of how catastrophic a failure
to clear routine immune responses canbe.
The rise and fall of an immune response
is exemplified by the well-documented
phenomenon of T cell clonal contraction,
also called peripheral deletion. Numbers
of responding T cells increase dramati-
cally, peak, and then decline quickly (of-
ten at a point presumed to reflect removal
of antigen), leaving a relatively small num-
ber of memory T cells. With an earlymodel
for such clonal contraction, it was found
that defects in the death receptor, CD95Rudolph, M.G., Stanfield, R.L., and Wilson, I.A.
(2006). Annu. Rev. Immunol. 24, 419–466.
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Hussey, R.E., Nathenson, S.G., Chang, H.C., Rein-
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), Hutcheson et al. (2008), and Wean
in the contraction phase of T cell res
(Fas), and its ligand CD95-L (FasL), can
play roles in this process (reviewed in
Green et al., 2003), a finding that initially
seemed to agreewith several other obser-
vations: (1) Mice or humans with defects
in either Fas ligand or its receptor have
a marked lymphoaccumulation and often
have accelerated autoimmune disease
(Rieux-Laucat et al., 2003), (2) activation-
induced cell death in T cells, as a conse-
quence of restimulation of a previously
activated T cell, can be due to Fas-FasL
interactions (reviewed in Green et al.,
2003), and (3) although apoptosis by this
mechanismwas the only form understood
at the time, introduction of a Bcl2 trans-
gene (known to block apoptosis in some
settings) expressed in T cells made the
lymphoaccumulation much worse (Reap
et al., 1995).
It emerged, however, that there were
a number of problems with this view.
Bcl-2 (and other antiapoptotic members
of this family) inhibits the mitochondrial
pathway of apoptosis, which is only
sometimes important in death receptor
(such as Fas)-mediated cell death and ap-
pears to have little or no role in Fas-medi-
ated T cell death (Strasser et al., 1995).
Further, the expansion of T cells in mice
or humans lacking functional Fas or FasL
is predominantly that of an unusual subset
(B220+, CD3+, CD4, CD8) that does not
arise in normal immune responses. But
perhaps most importantly, the process
Immunityvon Boehmer, H. (2005). Natl. Rev. 5, 571–
577.
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t et al. (2008) highlight the roles of
ponses and reveal consequences
of peripheral deletion was found to be
far more dependent on the proapoptotic
Bcl-2 family protein Bim, than on the death
receptor, Fas (Hildeman et al., 2002). Bim
is a trigger of the mitochondrial pathway
of apoptosis and plays a prominent role
in cell death caused by cytokine depriva-
tion of T cells. Therefore, clonal contrac-
tion of T cells during an immune response
appeared to be apoptosis due to limited
growth and survival factors, rather than
an active ligation of death receptors.
Three papers in this issue of Immunity
(Hughes et al., 2008; Hutcheson et al.,
2008; Weant et al., 2008) now help to re-
solve this. Mice deficient in both Fas func-
tion and Bim have normal development
(including lymphoid development) but
over time display enormous expansion
of lymphoid (and some myeloid) cells.
This includes profound increases in
memory T cell pools (both central and
effector), as well as B cells and macro-
phages. The B220+, CD3+ T cell subset
seen in Fas-defective individuals was
also greatly expanded. Stunningly, lym-
phoid organs in these mice can expand
to represent half of themass of the animal.
Clearly, this is an example of redun-
dancy in a cell-death process, but who
is backing up whom? Bim is a critical
player in the apoptotic response to dep-
rivation from survival factors, especially
in hematopoietic cells, and accumulates
under these conditions to engage the
28, February 2008 ª2008 Elsevier Inc. 141
